CN109991411B - 一种检测待测样本中目标抗体的免疫测定方法及其应用 - Google Patents
一种检测待测样本中目标抗体的免疫测定方法及其应用 Download PDFInfo
- Publication number
- CN109991411B CN109991411B CN201711476497.4A CN201711476497A CN109991411B CN 109991411 B CN109991411 B CN 109991411B CN 201711476497 A CN201711476497 A CN 201711476497A CN 109991411 B CN109991411 B CN 109991411B
- Authority
- CN
- China
- Prior art keywords
- antibody
- immune complex
- human
- antigen
- target antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000003018 immunoassay Methods 0.000 title claims abstract description 47
- 239000000427 antigen Substances 0.000 claims abstract description 97
- 108091007433 antigens Proteins 0.000 claims abstract description 97
- 102000036639 antigens Human genes 0.000 claims abstract description 97
- 238000000034 method Methods 0.000 claims abstract description 96
- 238000009739 binding Methods 0.000 claims abstract description 21
- 230000027455 binding Effects 0.000 claims abstract description 20
- 210000002966 serum Anatomy 0.000 claims description 69
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 65
- 238000006243 chemical reaction Methods 0.000 claims description 58
- 230000003053 immunization Effects 0.000 claims description 53
- 238000002965 ELISA Methods 0.000 claims description 52
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 48
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 44
- 241001465754 Metazoa Species 0.000 claims description 44
- 238000002649 immunization Methods 0.000 claims description 38
- 238000005406 washing Methods 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 31
- 238000001514 detection method Methods 0.000 claims description 31
- 150000001875 compounds Chemical class 0.000 claims description 27
- 241000699670 Mus sp. Species 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 229960002685 biotin Drugs 0.000 claims description 23
- 235000020958 biotin Nutrition 0.000 claims description 23
- 239000011616 biotin Substances 0.000 claims description 23
- 238000004113 cell culture Methods 0.000 claims description 23
- 239000012228 culture supernatant Substances 0.000 claims description 22
- 210000004989 spleen cell Anatomy 0.000 claims description 21
- 239000003480 eluent Substances 0.000 claims description 20
- 108010090804 Streptavidin Proteins 0.000 claims description 19
- 239000003153 chemical reaction reagent Substances 0.000 claims description 18
- 238000010367 cloning Methods 0.000 claims description 18
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 15
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 15
- 239000007790 solid phase Substances 0.000 claims description 15
- 238000001042 affinity chromatography Methods 0.000 claims description 14
- 239000000047 product Substances 0.000 claims description 14
- 238000003259 recombinant expression Methods 0.000 claims description 14
- 239000002299 complementary DNA Substances 0.000 claims description 13
- 238000011068 loading method Methods 0.000 claims description 13
- 238000012216 screening Methods 0.000 claims description 12
- 238000012360 testing method Methods 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 10
- 239000007787 solid Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 241001515965 unidentified phage Species 0.000 claims description 9
- 238000012408 PCR amplification Methods 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 230000005284 excitation Effects 0.000 claims description 8
- 206010003445 Ascites Diseases 0.000 claims description 7
- 239000012736 aqueous medium Substances 0.000 claims description 7
- 230000005281 excited state Effects 0.000 claims description 7
- 239000003550 marker Substances 0.000 claims description 7
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 230000003321 amplification Effects 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 239000013522 chelant Substances 0.000 claims description 4
- 230000000149 penetrating effect Effects 0.000 claims description 4
- 238000005185 salting out Methods 0.000 claims description 4
- 238000013459 approach Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 229910052747 lanthanoid Inorganic materials 0.000 claims description 3
- 150000002602 lanthanoids Chemical class 0.000 claims description 3
- 238000010839 reverse transcription Methods 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 description 25
- 210000003743 erythrocyte Anatomy 0.000 description 24
- 108020003175 receptors Proteins 0.000 description 24
- 239000000243 solution Substances 0.000 description 21
- 239000000370 acceptor Substances 0.000 description 19
- 241000283973 Oryctolagus cuniculus Species 0.000 description 17
- 101710132601 Capsid protein Proteins 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
- 239000007853 buffer solution Substances 0.000 description 11
- 239000011248 coating agent Substances 0.000 description 10
- 238000000576 coating method Methods 0.000 description 10
- 241000283707 Capra Species 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 230000006058 immune tolerance Effects 0.000 description 8
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000009870 specific binding Effects 0.000 description 7
- 238000010828 elution Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000007910 cell fusion Effects 0.000 description 5
- 238000007865 diluting Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000001131 transforming effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000012224 working solution Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- -1 antibodies Substances 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 238000011587 new zealand white rabbit Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 150000003839 salts Chemical group 0.000 description 3
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- BVTJGGGYKAMDBN-UHFFFAOYSA-N Dioxetane Chemical compound C1COO1 BVTJGGGYKAMDBN-UHFFFAOYSA-N 0.000 description 2
- WZELXJBMMZFDDU-UHFFFAOYSA-N Imidazol-2-one Chemical group O=C1N=CC=N1 WZELXJBMMZFDDU-UHFFFAOYSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 150000001491 aromatic compounds Chemical class 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000003163 cell fusion method Methods 0.000 description 2
- 238000013373 clone screening Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000003504 photosensitizing agent Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- BZYUMXXOAYSFOW-UHFFFAOYSA-N 2,3-dimethylthiophene Chemical compound CC=1C=CSC=1C BZYUMXXOAYSFOW-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000206761 Bacillariophyta Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 125000002009 alkene group Chemical group 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000002769 b effector cell Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- 229930002868 chlorophyll a Natural products 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 239000001752 chlorophylls and chlorophyllins Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 125000002534 ethynyl group Chemical class [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229920000592 inorganic polymer Polymers 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 229930187593 rose bengal Natural products 0.000 description 1
- 229940081623 rose bengal Drugs 0.000 description 1
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 1
- VDNLFJGJEQUWRB-UHFFFAOYSA-N rose bengal free acid Chemical compound OC(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C(O)=C(I)C=C21 VDNLFJGJEQUWRB-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
稀释倍数 | 1# | 2# | 3# | 4# | 5# | 6# | 7# | 8# |
10000 | 0.1106 | 0.1694 | 0.1403 | 0.1220 | 0.1446 | 0.1216 | 0.1267 | 0.1145 |
1000 | 0.1394 | 0.5199 | 0.3102 | 0.4200 | 0.3227 | 0.1721 | 0.1084 | 0.2842 |
100 | 0.9874 | 1.8699 | 1.3351 | 1.6106 | 1.3367 | 0.7115 | 0.5412 | 1.1412 |
10 | 1.5354 | 2.5083 | 2.4371 | 2.5663 | 2.5656 | 1.6474 | 1.5641 | 1.6241 |
稀释倍数 | 1# | 2# | 3# | 4# | 5# | 6# | 7# | 8# |
10000 | 0.1124 | 0.1854 | 0.1547 | 0.1624 | 0.1154 | 0.1136 | 0.1101 | 0.1254 |
1000 | 0.3145 | 0.9654 | 0.6584 | 0.8541 | 0.4651 | 0.3895 | 0.1954 | 0.5412 |
100 | 1.3254 | 1.6741 | 1.4214 | 1.5821 | 1.2451 | 1.1874 | 0.8941 | 1.3512 |
10 | 2.5284 | 2.6541 | 2.6142 | 2.6421 | 2.5641 | 2.4254 | 1.5421 | 2.5142 |
稀释倍数 | 1# | 2# | 3# | 4# | 5# | 6# | 7# | 8# |
10000 | 0.1074 | 0.5108 | 0.3250 | 0.3951 | 0.2055 | 0.1487 | 0.1243 | 0.2141 |
1000 | 0.6254 | 1.7009 | 1.3473 | 1.5012 | 1.0031 | 0.6207 | 0.3089 | 1.1254 |
100 | 1.9421 | 2.6115 | 2.5272 | 2.5142 | 2.3392 | 1.8743 | 1.1943 | 2.3241 |
10 | 2.6521 | 2.6685 | 2.6057 | 2.5254 | 2.6493 | 2.6583 | 2.0444 | 2.5214 |
Claims (33)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711476497.4A CN109991411B (zh) | 2017-12-29 | 2017-12-29 | 一种检测待测样本中目标抗体的免疫测定方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711476497.4A CN109991411B (zh) | 2017-12-29 | 2017-12-29 | 一种检测待测样本中目标抗体的免疫测定方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109991411A CN109991411A (zh) | 2019-07-09 |
CN109991411B true CN109991411B (zh) | 2023-01-20 |
Family
ID=67108802
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711476497.4A Active CN109991411B (zh) | 2017-12-29 | 2017-12-29 | 一种检测待测样本中目标抗体的免疫测定方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109991411B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989007271A1 (en) * | 1988-01-28 | 1989-08-10 | E.I. Du Pont De Nemours And Company | Immunoassays using monoclonal antibodies directed against natural binding proteins |
US4925788A (en) * | 1986-10-24 | 1990-05-15 | Immunicon Corporation | Immunoassay system and procedure based on precipitin-like interaction between immune complex and Clq or other non-immunospecific factor |
CN103217533A (zh) * | 2012-01-21 | 2013-07-24 | 厦门大学 | Anti-HBc 定量检测方法及其在监控慢性乙肝患者病情发展和预测治疗疗效中的用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08193999A (ja) * | 1995-01-13 | 1996-07-30 | Sekisui Chem Co Ltd | 免疫測定法 |
US8093018B2 (en) * | 2008-05-20 | 2012-01-10 | Otsuka Pharmaceutical Co., Ltd. | Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same |
DE102008049601A1 (de) * | 2008-09-30 | 2010-04-01 | Siemens Healthcare Diagnostics Products Gmbh | Antikörper zur Bestimmung des Prothrombin-Fragments F2/F1+2 in einem homogenen Immunoassay |
CN102735833B (zh) * | 2012-07-09 | 2015-01-21 | 沃克(天津)生物科技有限公司 | 甲状腺过氧化物酶抗体均相发光免疫分析试剂盒及其检测方法 |
CN102944672B (zh) * | 2012-11-16 | 2015-05-20 | 李方和 | 采用光激发化学发光免疫分析对血清中的待测靶物质进行定性与定量检测的方法 |
CN105785030A (zh) * | 2016-03-09 | 2016-07-20 | 博阳生物科技(上海)有限公司 | 一种血清特异性IgE光激化学发光免疫分析试剂盒 |
CN105758835B (zh) * | 2016-05-04 | 2018-03-27 | 成都爱兴生物科技有限公司 | 一种均相免疫分析poct检测方法及使用该检测方法的系统 |
CN106699883B (zh) * | 2016-12-19 | 2020-08-07 | 中国兽医药品监察所 | 豚鼠补体C1q-B单克隆抗体60G4的制备与应用 |
CN106596958B (zh) * | 2016-12-19 | 2018-07-20 | 中国兽医药品监察所 | 布鲁氏菌病cf-elisa抗体检测试剂盒 |
-
2017
- 2017-12-29 CN CN201711476497.4A patent/CN109991411B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4925788A (en) * | 1986-10-24 | 1990-05-15 | Immunicon Corporation | Immunoassay system and procedure based on precipitin-like interaction between immune complex and Clq or other non-immunospecific factor |
WO1989007271A1 (en) * | 1988-01-28 | 1989-08-10 | E.I. Du Pont De Nemours And Company | Immunoassays using monoclonal antibodies directed against natural binding proteins |
CN103217533A (zh) * | 2012-01-21 | 2013-07-24 | 厦门大学 | Anti-HBc 定量检测方法及其在监控慢性乙肝患者病情发展和预测治疗疗效中的用途 |
Also Published As
Publication number | Publication date |
---|---|
CN109991411A (zh) | 2019-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108051585A (zh) | 一种均相免疫检测试剂盒、检测方法及其应用 | |
JP6715770B2 (ja) | モノクローナル抗tk1抗体 | |
EP0440044A1 (en) | Avoidance of human anti-mouse antibody interference in in vitro diagnostic testing | |
CN109709317B (zh) | 一种无基质效应的均相免疫检测试剂盒及其分析方法和应用 | |
US10816469B2 (en) | Kit for quantitatively determining substance to be measured in biological sample and method for quantitatively determining substance to be measured in biological sample | |
CN109991405B (zh) | 一种免疫检测试剂盒及其应用 | |
CN107102135A (zh) | 用于减少非特异性结合的免疫检验方法和试剂 | |
US10883986B2 (en) | Kit for quantitatively determining bile acid in biological sample, and method for quantitatively determining bile acid in biological sample | |
CN111732664B (zh) | 一种新型冠状病毒重组蛋白、兔-人嵌合抗体、其制备方法及应用 | |
CN114217076A (zh) | 检测目标抗-Carp抗体的均相免疫检测试剂盒及其应用 | |
CN111521779B (zh) | 一种丙型肝炎病毒抗原抗体联检方法、试剂盒 | |
CN109991411B (zh) | 一种检测待测样本中目标抗体的免疫测定方法及其应用 | |
CN114397442A (zh) | 检测14-3-3eta蛋白的均相免疫检测试剂盒及其应用 | |
CN110579597A (zh) | 检测14-3-3 eta蛋白的非均相化学发光免疫检测试剂盒及其应用 | |
CN110161232B (zh) | 检测抗ccp抗体的均相免疫检测试剂盒及其应用 | |
CN111217910B (zh) | 单克隆抗体对及其在检测髓过氧化物酶蛋白中的应用 | |
CN110161248B (zh) | 检测抗Carp抗体的均相免疫检测试剂盒及其应用 | |
CN109988241A (zh) | 一种特异性识别人免疫复合物的抗体及其制备方法和用途 | |
JP4663831B2 (ja) | モノクローナル抗体、細胞株及びn1,n12−ジアセチルスペルミンの測定法 | |
CN117554621A (zh) | 快速检测n末端b型脑钠肽的均相免疫试剂盒、制备方法、检测方法和装置 | |
CN110579592A (zh) | 检测14-3-3eta蛋白的非均相化学发光免疫检测试剂盒及其应用 | |
CN110579601A (zh) | 通过生物标记物联检体外评估类风湿性关节炎是否存在的方法 | |
WO1992019755A1 (en) | MONOCLONAL ANTIBODY AGAINST HUMAN β2-GLYCOPROTEIN I AND USE THEREOF | |
US11255849B2 (en) | Kit for quantitatively determining substance to be measured in biological sample | |
TWI363763B (en) | The measuring method for human orotate phosphoribosyl transferase protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 201210 floor 3 and 5, building 1, No. 88, Cailun Road, free trade zone, Pudong New Area, Shanghai Applicant after: BEYOND DIAGNOSTICS (SHANGHAI) Co.,Ltd. Applicant after: Kemei Diagnostic Technology Co.,Ltd. Address before: 201210 Shanghai City, Pudong New Area Free Trade Zone No. 88 five floor East Cailun Road Applicant before: BEYOND DIAGNOSTICS (SHANGHAI) Co.,Ltd. Applicant before: BEIJING CHEMCLIN BIOTECH Co.,Ltd. |
|
CB02 | Change of applicant information | ||
CB03 | Change of inventor or designer information |
Inventor after: Chen Yinghao Inventor after: Zhao Weiguo Inventor after: Liu Yuhui Inventor after: Li Lin Inventor before: Chen Yinghao Inventor before: Zhao Weiguo Inventor before: Li Huiqiang Inventor before: Liu Yuhui Inventor before: Li Lin |
|
CB03 | Change of inventor or designer information | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 200131 third and fifth floors, building 1, No. 88 Cailun Road, pilot Free Trade Zone, Pudong New Area, Shanghai Applicant after: Kemei Boyang diagnostic technology (Shanghai) Co.,Ltd. Applicant after: Kemei Diagnostic Technology Co.,Ltd. Address before: 201210 third and fifth floors, building 1, No. 88, Cailun Road, pilot Free Trade Zone, Pudong New Area, Shanghai Applicant before: BEYOND DIAGNOSTICS (SHANGHAI) Co.,Ltd. Applicant before: Kemei Diagnostic Technology Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20221021 Address after: 201210 East floor, first floor, building 7, No. 249 Faraday Road, pilot Free Trade Zone, Pudong New Area, Shanghai Applicant after: SHANGHAI SUOXIN BIOLOGICAL TECHNOLOGY Co.,Ltd. Address before: 200131 3rd and 5th floors, building 1, No.88 Cailun Road, Pudong New Area pilot Free Trade Zone, Shanghai Applicant before: Kemei Boyang diagnostic technology (Shanghai) Co.,Ltd. Applicant before: Kemei Diagnostic Technology Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |